A 15-minute appointment every 12 weeks gives clinicians a 0.15 percent sample of a patient's respiratory life. A typical COPD patient on stable treatment sees a respiratory clinician or COPD nurse specialist roughly every three months. Between visits, they occupy a monitoring gap. They may have a rescue pack, an action plan, and a GP surgery contact number. Clinically, however, they remain unseen until a planned review or an emergency department presentation.
This is not a case for more frequent routine appointments. That would not solve the problem and cannot be delivered at scale within current NHS capacity. The issue is that being unseen between visits has identifiable clinical costs. Those costs should be recognised before considering alternative monitoring approaches.
The Cost of Being Unseen
When COPD worsens between appointments, the course usually follows one of three patterns. In the first, the patient notices the change early, uses their rescue pack correctly, and recovers without clinical input. This is the intended result of self-management education and the best-case outcome.
In the second, decline is gradual. The patient adjusts to poorer function without recognising a clinical event that needs action, then attends a scheduled review with markedly lower FEV1 and poorer quality of life scores than at the previous visit. The clinician is left managing a problem that early intervention might have stopped from accelerating.
The third course is emergency admission. The patient reaches crisis, calls 999 or attends A&E, and is admitted. One in five COPD patients admitted acutely is readmitted within 30 days, a rate that has resisted population-level intervention despite years of work. For the NHS, each emergency COPD admission brings substantial system costs, while the patient bears the burden of functional recovery and psychological wellbeing.
The second and third courses have the same underlying feature: physiological decline came first, and intervention might have changed its course, but there was no way to identify it.
What Quarterly Reviews Capture
A 20-minute COPD review every three months shows the clinician the patient's status on one particular day. Spirometry, oxygen saturation, weight, medication review, CAT or MRC scoring, and a brief symptom review are all point-in-time measures. They show the patient's current position compared with three months ago, not what occurred between visits.
A patient may experience two moderate exacerbations during the preceding quarter and recover from both without contacting a clinician, then attend an annual review with spirometry little worse than the previous year. Each exacerbation may have accelerated long-term decline and imposed a recovery burden. Yet neither appears in the review record unless the patient reports it accurately, which may not happen if they managed the events themselves and viewed them as unremarkable.
Clinical records therefore often understate exacerbation frequency, especially for moderate events. The patient who attended A&E is recorded. The patient who used a rescue pack twice, cancelled plans for three weeks because of fatigue, and quietly returned to baseline often is not.
Limits of Self-Managed Plans
Self-management education and action plans are genuinely useful for patients who recognise their own early warning signs and have the health literacy and confidence to respond appropriately. When properly supported, self-management programmes show reasonably positive evidence for reducing emergency admissions.
Action plans depend on recognising symptoms, but recognition has limits. A patient with mild-to-moderate disease may have breathing changes detectable by an external monitor while experiencing only tiredness, slightly lower activity tolerance, or "not feeling great." They do not start the action plan because they do not see the change as a respiratory exacerbation. When symptoms become clear enough to prompt activation, the exacerbation is often already moderate-to-severe.
This is not a criticism of patients or self-management programmes. It reflects the inherent limits of proprioceptive awareness during gradual physiological change. People are poorly calibrated to notice slow movement from their own baseline, especially when that baseline has declined gradually over years.
The Clinical Data Gap
The monitoring gap has an uneven clinical impact. Usually, nothing happens between appointments and the gap causes no harm. The important events, exacerbations that accelerate decline or lead to admission, tend to occur while the patient is worsening without the clinician knowing. The gap costs most when the patient's condition is deteriorating.
This unevenness explains why passive continuous monitoring can be more useful than more frequent scheduled reviews for detecting deterioration. Scheduled reviews add contact at set intervals. Continuous monitoring directs clinical attention toward periods of deterioration, without asking the patient to become severe enough to seek contact first.
What Closing the Gap Takes
Not every COPD patient needs continuous monitoring. For stable, well-managed GOLD 1-2 patients with no exacerbation history, the gap is a limited clinical concern and difficult to justify on resource grounds. Closing it matters most for people with GOLD 3-4 disease, a prior exacerbation history, or an admission in the preceding year, the group facing the greatest downside from missing deterioration.
For this group, the interval between appointments is not a scheduling issue. It is a data issue, and one that can be addressed with technology available now, applied carefully and honestly within its current evidence base. We are building that technology while acknowledging that evidence on optimal deployment is still developing. The alternative is to wait for perfect evidence as patients in the monitoring gap continue along their present paths.